- Conditions
- Healthy Volunteers
- Interventions
- CC-90001, Placebo
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Depressive Disorder, Major
- Interventions
- SUVN-911, Placebo
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer
- Interventions
- CKD-703
- Drug
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Ohio City, Ohio
- Conditions
- Cardiomyopathy Due to Anthracyclines
- Interventions
- Allo-MSCs, Placebo
- Biological
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 7
- States / cities
- Stanford, California • Gainesville, Florida • Miami, Florida + 4 more
- Conditions
- Cardiovascular Disease
- Interventions
- Hemolink (hemoglobin raffimer IV solution)
- Drug
- Lead sponsor
- Hemosol
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 19
- States / cities
- San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
- Conditions
- Advanced Solid Tumor
- Interventions
- BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
- Conditions
- Healthy Volunteer, Atopic Dermatitis
- Interventions
- REGN20423, Placebo
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • West Hills, California + 5 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug:LM-102
- Drug
- Lead sponsor
- LaNova Medicines Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- California City, California • Indianapolis, Indiana • Detroit, Michigan + 3 more
- Conditions
- Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
- Interventions
- NM1F Injection, Pembrolizumab injection
- Drug
- Lead sponsor
- Hefei TG ImmunoPharma Co., Ltd.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Fairfax, Virginia
- Conditions
- Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
- Interventions
- ChampioNIR Ridaforolimus Eluting Peripheral Stent System
- Device
- Lead sponsor
- Medinol Ltd.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • New York, New York • Roslyn, New York
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- NNC9204-0530, liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 163 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
- Interventions
- AMG 794
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 1 more
- Conditions
- Solid Tumor, Advanced Solid Tumor
- Interventions
- M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW, M4344 80 mg BIW, M4344 160 mg BIW, M4344 300 mg BIW, M4344 450 mg BIW, M4344 700 mg BIW, M4344 1050 mg BIW, M4344 1200 mg BIW, M4344 100 mg BID, M4344 150 mg QD, M4344 250 mg QD, M4344 350 mg QD, M4344 400 mg, M4344 500 mg, Carboplatin
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more
- Conditions
- Presumptive NAFLD
- Interventions
- EDP 305, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- VX-634, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more
- Conditions
- Infections, Bacterial
- Interventions
- 500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Undefined
- Interventions
- MyMD1, Placebo
- Drug
- Lead sponsor
- TNF Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- West Palm Beach, Florida
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986490, Bevacizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • La Jolla, California • Orange, California + 14 more
- Conditions
- Solid Tumor, Adult
- Interventions
- CX-2051, Bevacizumab
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Boston, Massachusetts • The Bronx, New York + 5 more
- Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Interventions
- RAD140
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Metabolic Disorders, Non-alcoholic Steatohepatitis
- Interventions
- AZD2693, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy
- Interventions
- RVP-001, Placebo
- Drug
- Lead sponsor
- Reveal Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Atopic Dermatitis
- Interventions
- CEE321
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland